TFF Pharmaceuticals (NASDAQ:TFFP) PT Lowered to $44.00 at Roth Mkm

TFF Pharmaceuticals (NASDAQ:TFFP) had its price objective lowered by investment analysts at Roth Mkm from $56.00 to $44.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock.

TFF Pharmaceuticals Stock Performance

TFFP stock traded down $0.52 on Thursday, hitting $6.07. 37,819 shares of the company were exchanged, compared to its average volume of 25,371. TFF Pharmaceuticals has a twelve month low of $4.55 and a twelve month high of $21.25. The business’s fifty day moving average is $6.69 and its two-hundred day moving average is $7.33.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Worth Venture Partners LLC increased its holdings in shares of TFF Pharmaceuticals by 66.2% in the 3rd quarter. Worth Venture Partners LLC now owns 646,832 shares of the company’s stock worth $226,000 after acquiring an additional 257,722 shares during the period. AIGH Capital Management LLC boosted its holdings in shares of TFF Pharmaceuticals by 70.7% in the third quarter. AIGH Capital Management LLC now owns 2,655,235 shares of the company’s stock worth $929,000 after buying an additional 1,099,709 shares during the period. UBS Group AG boosted its holdings in shares of TFF Pharmaceuticals by 13.8% in the first quarter. UBS Group AG now owns 129,780 shares of the company’s stock worth $89,000 after buying an additional 15,709 shares during the period. DRW Securities LLC acquired a new stake in shares of TFF Pharmaceuticals during the fourth quarter worth approximately $1,050,000. Finally, Millennium Management LLC acquired a new stake in shares of TFF Pharmaceuticals during the fourth quarter worth approximately $200,000. 15.25% of the stock is currently owned by institutional investors.

TFF Pharmaceuticals Company Profile

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.